Opinion
Video
Key Takeaways
- Development of therapies that halt or reverse IPF and PAH progression is a significant unmet need.
- Improved diagnostic tools are essential for earlier detection and intervention in IPF and PAH.
SHOW MORE
Steven Nathan, MD, discusses the abstract “Predicting Long-Term Survival in Patients With Idiopathic Pulmonary Fibrosis: Data From the IPF-PRO Registry,” which aimed to identify key predictors of long-term survival in IPF using data from the IPF-PRO Registry; the study employed a classification and regression tree model to analyze variables such as FVC percent predicted, oxygen use, BMI, and age, and found that factors such as oxygen use and FVC levels were strong predictors of survival beyond 5 years.
- Briefly describe the abstract “Predicting Long-Term Survival in Patients With Idiopathic Pulmonary Fibrosis: Data From The IPF-PRO Registry.”
- What was the objective of this study?
- How was this study designed/what methodology was used?
- What results were presented?
